Last updated: March 1, 2026
What is the Drug with NDC 53489-0387?
The National Drug Code (NDC) 53489-0387 identifies Ravicti (glycerol phenylbutyrate) oral liquid. Approved by the FDA in 2015, Ravicti is used to reduce ammonia levels in patients with urea cycle disorders (UCD), a rare genetic condition impairing ammonia detoxification.
Market Landscape
Market Size and Patient Population
- Target Population: Urea cycle disorder affects approximately 1 in 40,000 individuals in the U.S., with an estimated 250-350 patients actively treated with ammonia detoxifiers.[1]
- Market Penetration: Ravicti entered a niche market dominated by sodium phenylbutyrate (Buphenyl), with limited alternative treatments.
- Competitive Products:
- Buphenyl (sodium phenylbutyrate): Established, generic availability.
- Urea cycle disorder: No cure; treatment options are primarily managing ammonia levels.
Market Dynamics
- Pricing Strategy: Ravicti is priced significantly higher than generic alternatives due to patent protection and orphan drug status.
- Insurance Coverage: Coverage is variable, with high out-of-pocket costs contributing to limited adoption in some cases.
- Regulatory Pathway: Orphan drug designation provides market exclusivity until 2022, with possible extensions.[2]
Manufacturing and Supply Chain Considerations
- Ravicti is produced by Horizon Therapeutics. Manufacturing disruptions could influence supply and pricing.
- The drug's liquid formulation simplifies administration but requires cold chain logistics.
Price History and Projections
Past Pricing Data
- Initial Launch Price: Approximately $300,000 per year per patient (2015).
- Price Trends:
- Slight reductions noted after biosimilar entry in other rare disease treatments.
- No biosimilar competition exists currently owing to orphan drug exclusivity.
Current Pricing (2023)
- Average Wholesale Price (AWP): Approximately $250,000 to $300,000 annually per patient.
- Average Patient Cost: Often exceeds $27,000 per month after insurance adjustments.[3]
Future Pricing Trends
| Year |
Projected Price Range ($ per year) |
Assumptions |
| 2024 |
$240,000–$280,000 |
No major market entry, patent protection intact. |
| 2025 |
$230,000–$270,000 |
Patent exclusivity extended, potential insurance negotiations. |
| 2026 |
$200,000–$260,000 |
Possible biosimilar entry in niche markets, standardization of acquisition. |
| 2030 |
$180,000–$220,000 |
Patent expiry approaches; generic entry likely. |
Key Factors Influencing Price
- Patent and Exclusivity: Market exclusivity protects pricing until 2022–2024, after which biosimilar competition could depress prices.
- Orphan Drug Regulations: Provide market exclusivity but limit new competitive entries.
- Insurance Reimbursement: High coverage restricts out-of-pocket costs but influences pricing negotiations.
- Manufacturing Costs: Stable, given Horizon's established supply chain.
Competitive Threats and Strategic Considerations
- Biosimilars and Generics: Entry likely post-2022, with price reductions estimated at 30–50%.
- New Therapies: Research into alternative ammonia-lowering agents may impact demand.
- Regulatory Changes: Policy shifts could extend or shorten exclusivity periods or influence reimbursement frameworks.
Summary
Ravicti (NDC 53489-0387) maintains a high-price, low-competition profile due to regulatory exclusivity. Market size remains limited by the rarity of UCD. Price projections show a gradual decline starting in 2024, driven by patent expiration and biosimilar entry. The primary strategy for manufacturers and investors involves monitoring patent status, potential biosimilar developments, and insurance reimbursement trends.
Key Takeaways
- Ravicti's current annual cost exceeds $250,000 per patient.
- Market exclusivity protects high prices until approximately 2024.
- Biosimilar competition is expected to emerge post-2022, likely reducing prices by up to 50%.
- The total target population limits revenue potential despite high individual treatment costs.
- Policy, patent, and reimbursement landscapes significantly influence future pricing.
Frequently Asked Questions
1. When will generic or biosimilar versions of Ravicti be available?
Biosimilar versions could enter the market after patent expiration, expected around 2024–2025, depending on regulatory approval and patent litigation outcomes.
2. How does the rarity of UCD impact market growth?
The small patient population limits revenue expansion despite high prices, making the market attractive primarily for niche players and incentivizing orphan drug status protections.
3. What are the main factors affecting Ravicti’s price decline?
Patent expiration, biosimilar entry, insurance reimbursement policies, and manufacturing costs.
4. How do insurance companies influence Ravicti’s market adoption?
High insurance coverage reduces out-of-pocket costs, supporting utilization, but insurance negotiations can also pressure manufacturers to lower prices.
5. Are there any ongoing developments that could replace Ravicti?
Research into alternative ammonia-lowering therapies, gene therapy, or enzyme replacement could impact demand for Ravicti in the future.
References
[1] National Institutes of Health. (2021). Urea cycle disorders. https://rarediseases.info.nih.gov/diseases/5834/urea-cycle-disorders
[2] FDA. (2015). Ravicti (glycerol phenylbutyrate) approval letter. https://www.fda.gov/drugs/resources-information-approved-drugs/ravicti
[3] IQVIA. (2022). US Prescription Price Data.
